|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
WO1990005144A1
(en)
|
1988-11-11 |
1990-05-17 |
Medical Research Council |
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
AU6290090A
(en)
|
1989-08-29 |
1991-04-08 |
University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
WO1992009690A2
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with altered binding properties
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
US5144088A
(en)
|
1991-04-26 |
1992-09-01 |
Aristech Chemical Corporation |
Manufacture of neopentyl glycol (I)
|
|
CA2103059C
(en)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
JP3951062B2
(ja)
|
1991-09-19 |
2007-08-01 |
ジェネンテック・インコーポレーテッド |
少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
EP1997894B1
(en)
|
1992-02-06 |
2011-03-30 |
Novartis Vaccines and Diagnostics, Inc. |
Biosynthetic binding protein for cancer marker
|
|
PT752248E
(pt)
|
1992-11-13 |
2001-01-31 |
Idec Pharma Corp |
Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
US5798100A
(en)
|
1994-07-06 |
1998-08-25 |
Immunomedics, Inc. |
Multi-stage cascade boosting vaccine
|
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
DK0979281T3
(da)
|
1997-05-02 |
2005-11-21 |
Genentech Inc |
Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
JP2002506353A
(ja)
|
1997-06-24 |
2002-02-26 |
ジェネンテック・インコーポレーテッド |
ガラクトシル化糖タンパク質の方法及び組成物
|
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
|
WO1999022764A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
|
ATE531812T1
(de)
|
1997-12-05 |
2011-11-15 |
Scripps Research Inst |
Humanisierung von nager-antikörpern
|
|
DK1068241T3
(da)
|
1998-04-02 |
2008-02-04 |
Genentech Inc |
Antistofvarianter og fragmenter deraf
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
PT1071700E
(pt)
|
1998-04-20 |
2010-04-23 |
Glycart Biotechnology Ag |
Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
|
DE69939939D1
(de)
|
1998-08-11 |
2009-01-02 |
Idec Pharma Corp |
Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern
|
|
ES2351149T3
(es)
|
1998-11-09 |
2011-02-01 |
Biogen Idec Inc. |
Anticuerpo quimérico dirigido contra cd20, el rituxan, para uso en el tratamiento de la leucemia linfocítica crónica.
|
|
ES2694002T3
(es)
|
1999-01-15 |
2018-12-17 |
Genentech, Inc. |
Polipéptido que comprende una región Fc de IgG1 humana variante
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
WO2000061739A1
(fr)
|
1999-04-09 |
2000-10-19 |
Kyowa Hakko Kogyo Co., Ltd. |
Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
|
|
EP1222292B1
(en)
|
1999-10-04 |
2005-08-31 |
Medicago Inc. |
Method for regulating transcription of foreign genes in the presence of nitrogen
|
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
|
US7504256B1
(en)
|
1999-10-19 |
2009-03-17 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for producing polypeptide
|
|
EP1240319A1
(en)
|
1999-12-15 |
2002-09-18 |
Genentech, Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
|
DK1242438T3
(da)
|
1999-12-29 |
2007-02-12 |
Immunogen Inc |
Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse
|
|
PT2857516T
(pt)
|
2000-04-11 |
2017-08-28 |
Genentech Inc |
Anticorpos multivalentes e utilizações dos mesmos
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
MXPA03002974A
(es)
|
2000-10-06 |
2004-05-05 |
Kyowa Hakko Kogyo Kk |
Celulas que producen composiciones de anticuerpo.
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
KR100857943B1
(ko)
|
2000-11-30 |
2008-09-09 |
메다렉스, 인코포레이티드 |
인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
|
|
CA2838062C
(en)
|
2001-08-03 |
2015-12-22 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
MXPA04002593A
(es)
|
2001-09-18 |
2004-05-31 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumor.
|
|
NZ532526A
(en)
|
2001-10-25 |
2007-01-26 |
Genentech Inc |
Compositions comprising a glycoprotein having a Fc region
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
AU2003236019A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
|
|
WO2003084569A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Drug containing antibody composition
|
|
JPWO2003085118A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物の製造方法
|
|
US20040259150A1
(en)
|
2002-04-09 |
2004-12-23 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
|
|
MXPA04009924A
(es)
|
2002-04-09 |
2005-07-01 |
Kyowa Hakko Kogyo Kk |
Celulas de genoma modificado.
|
|
JP4628679B2
(ja)
|
2002-04-09 |
2011-02-09 |
協和発酵キリン株式会社 |
Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
|
|
CA2488441C
(en)
|
2002-06-03 |
2015-01-27 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
AR042485A1
(es)
|
2002-12-16 |
2005-06-22 |
Genentech Inc |
Anticuerpo humanizado que se une al cd20 humano
|
|
WO2004065416A2
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
NZ543712A
(en)
|
2003-06-05 |
2008-06-30 |
Genentech Inc |
Combination therapy for B cell disorders
|
|
AU2004279742A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Fused protein composition
|
|
AU2004280065A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
|
|
TR201809892T4
(tr)
|
2003-11-05 |
2018-07-23 |
Roche Glycart Ag |
Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
|
|
CN104998273A
(zh)
|
2003-11-06 |
2015-10-28 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
|
GB0404187D0
(en)
|
2004-02-25 |
2004-03-31 |
Biotransformations Ltd |
Binding agents
|
|
WO2005097832A2
(en)
|
2004-03-31 |
2005-10-20 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
|
CA2885854C
(en)
|
2004-04-13 |
2017-02-21 |
F. Hoffmann-La Roche Ag |
Anti-p-selectin antibodies
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
EP3088004B1
(en)
|
2004-09-23 |
2018-03-28 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
CN101198698B
(zh)
|
2005-03-31 |
2014-03-19 |
中外制药株式会社 |
通过调节多肽缔合制备多肽的方法
|
|
DK1874821T3
(da)
|
2005-04-26 |
2013-07-08 |
Trion Pharma Gmbh |
Kombination af antistoffer med glykokortikoider til behandling af kræft
|
|
EP2439273B1
(en)
|
2005-05-09 |
2019-02-27 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
US8219149B2
(en)
|
2005-06-29 |
2012-07-10 |
Nokia Corporation |
Mobile communication terminal
|
|
KR101888321B1
(ko)
|
2005-07-01 |
2018-08-13 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
WO2007018316A1
(ja)
|
2005-08-09 |
2007-02-15 |
Takeda Pharmaceutical Company Limited |
癌の予防・治療剤
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP3770174A1
(en)
|
2005-10-11 |
2021-01-27 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
ES2577292T3
(es)
|
2005-11-07 |
2016-07-14 |
Genentech, Inc. |
Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
|
|
US20070237764A1
(en)
|
2005-12-02 |
2007-10-11 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
|
EP1820513A1
(en)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
|
|
ES2395969T3
(es)
|
2006-03-24 |
2013-02-18 |
Merck Patent Gmbh |
Dominios de proteínas heterodiméricas genéticamente modificados
|
|
EP2016101A2
(en)
|
2006-05-09 |
2009-01-21 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
|
MX380352B
(es)
|
2006-06-12 |
2025-03-12 |
Aptevo Res & Development Llc |
Proteinas de union multivalentes monocatenarias con funcion efectora.
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
RU2561457C2
(ru)
|
2007-04-03 |
2015-08-27 |
Эмджен Рисерч (Мьюник) Гмбх |
Cd3-эпсилон-связывающий домен с межвидовой специфичностью
|
|
WO2008119566A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific bispecific binders
|
|
PT2520590T
(pt)
|
2007-04-03 |
2018-11-14 |
Amgen Res Munich Gmbh |
Domínio de ligação específico de espécies cruzadas
|
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
|
RS53595B1
(sr)
|
2007-07-16 |
2015-02-27 |
Genentech, Inc. |
Anti-cd79b antitela i imunokonjugati i metode upotrebe
|
|
JP6035009B2
(ja)
|
2007-08-22 |
2016-11-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
|
|
EP2225275A4
(en)
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
PROTEIN FORMULATION
|
|
CA2708951A1
(en)
|
2007-12-21 |
2009-07-09 |
Genetech, Inc. |
Crystallization of anti-cd20 antibodies
|
|
EP2238169A1
(en)
|
2007-12-26 |
2010-10-13 |
Biotest AG |
Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
|
|
WO2009106096A1
(en)
|
2008-02-27 |
2009-09-03 |
Fresenius Biotech Gmbh |
Treatment of resistant tumors with trifunctional antibodies
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
MX2011002250A
(es)
|
2008-08-25 |
2011-08-17 |
Amplimmune Inc |
Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
|
|
KR20140133588A
(ko)
|
2008-11-17 |
2014-11-19 |
제넨테크, 인크. |
생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제
|
|
US20110178279A1
(en)
|
2009-08-03 |
2011-07-21 |
Williams John C |
Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies
|
|
WO2010077643A1
(en)
|
2008-12-08 |
2010-07-08 |
Tegopharm Corporation |
Masking ligands for reversible inhibition of multivalent compounds
|
|
US8895702B2
(en)
|
2008-12-08 |
2014-11-25 |
City Of Hope |
Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
|
|
US8217149B2
(en)
|
2008-12-09 |
2012-07-10 |
Genentech, Inc. |
Anti-PD-L1 antibodies, compositions and articles of manufacture
|
|
SG174930A1
(en)
|
2009-04-01 |
2011-11-28 |
Genentech Inc |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
|
WO2010129304A2
(en)
|
2009-04-27 |
2010-11-11 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
ES2865648T3
(es)
|
2009-06-26 |
2021-10-15 |
Regeneron Pharma |
Anticuerpos biespecíficos fácilmente aislados con formato de inmunoglobulina nativa
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
MX2012002766A
(es)
|
2009-09-03 |
2012-04-02 |
Genentech Inc |
Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
|
|
US20120191435A1
(en)
|
2009-09-25 |
2012-07-26 |
Shanghai National Engineering Research Center Of Antibody Medicine Co., Ltd. |
Method of acquiring proteins with high affinity by computer aided design
|
|
JP2013512251A
(ja)
|
2009-11-24 |
2013-04-11 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
|
|
PT2519543T
(pt)
|
2009-12-29 |
2016-10-07 |
Emergent Product Dev Seattle |
Proteínas de ligação de heterodímero e suas utilizações
|
|
US20130129723A1
(en)
|
2009-12-29 |
2013-05-23 |
Emergent Product Development Seattle, Llc |
Heterodimer Binding Proteins and Uses Thereof
|
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究（慕尼黑）有限責任公司 |
跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
|
|
US9150663B2
(en)
|
2010-04-20 |
2015-10-06 |
Genmab A/S |
Heterodimeric antibody Fc-containing proteins and methods for production thereof
|
|
WO2011143545A1
(en)
|
2010-05-14 |
2011-11-17 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
|
US9193791B2
(en)
|
2010-08-03 |
2015-11-24 |
City Of Hope |
Development of masked therapeutic antibodies to limit off-target effects
|
|
JP5753903B2
(ja)
|
2010-08-24 |
2015-07-22 |
ロシュ グリクアート アーゲー |
活性化可能な二重特異性抗体
|
|
US8962804B2
(en)
|
2010-10-08 |
2015-02-24 |
City Of Hope |
Meditopes and meditope-binding antibodies and uses thereof
|
|
AU2011325833C1
(en)
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
SMT201700250T1
(it)
|
2010-11-10 |
2017-07-18 |
Amgen Res Munich Gmbh |
Prevenzione di effetti avversi provocati da domini leganti cd3 specifici
|
|
EP4279513A3
(en)
|
2010-11-30 |
2024-02-28 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
|
CA2818635C
(en)
|
2010-12-06 |
2021-06-15 |
National Reseach Council Of Canada |
Antibodies selective for cells presenting erbb2 at high density
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
JP6101638B2
(ja)
|
2011-03-03 |
2017-03-22 |
ザイムワークス，インコーポレイテッド |
多価ヘテロマルチマー足場設計及び構築物
|
|
WO2012123949A1
(en)
|
2011-03-17 |
2012-09-20 |
Ramot At Tel-Aviv University Ltd. |
Bi- and monospecific, asymmetric antibodies and methods of generating the same
|
|
US9683052B2
(en)
|
2011-03-25 |
2017-06-20 |
Glenmark Pharmaceuticals S.A. |
Hetero-dimeric immunoglobulins
|
|
SI2691417T2
(sl)
|
2011-03-29 |
2025-05-30 |
Roche Glycart Ag |
FC variante protitelesa
|
|
ES2669310T3
(es)
|
2011-04-20 |
2018-05-24 |
Medimmune, Llc |
Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
|
|
US20140170149A1
(en)
|
2011-04-20 |
2014-06-19 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
CN107903325B
(zh)
|
2011-05-16 |
2021-10-29 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
|
BR112013029893A2
(pt)
|
2011-05-21 |
2017-05-30 |
Macrogenics Inc |
molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica
|
|
RU2650775C2
(ru)
|
2011-08-23 |
2018-04-17 |
Рош Гликарт Аг |
Биспецифические антигенсвязывающие молекулы
|
|
EP2578230A1
(en)
|
2011-10-04 |
2013-04-10 |
Trion Pharma Gmbh |
Removal of Tumor Cells from Intraoperative Autologous Blood Salvage
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US20130165638A1
(en)
|
2011-12-27 |
2013-06-27 |
Development Center For Biotechnology |
Light chain-bridged bispecific antibody
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
EP2820047B1
(en)
|
2012-03-01 |
2018-04-25 |
Amgen Research (Munich) GmbH |
Long life polypeptide binding molecules
|
|
US9175082B2
(en)
|
2012-05-31 |
2015-11-03 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
|
SG11201408646VA
(en)
|
2012-07-06 |
2015-01-29 |
Genmab Bv |
Dimeric protein with triple mutations
|
|
US20140030280A1
(en)
|
2012-07-09 |
2014-01-30 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates
|
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
JP6571527B2
(ja)
|
2012-11-21 |
2019-09-04 |
ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドＷｕｈａｎ Ｙｚｙ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． |
二重特異性抗体
|
|
CA2889298C
(en)
|
2012-11-30 |
2024-01-02 |
Anton Belousov |
Identification of patients in need of pd-l1 inhibitor cotherapy
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
KR102064230B1
(ko)
|
2013-02-15 |
2020-01-13 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
키메라 항원 수용체 및 이의 이용 방법
|
|
EP2769989A1
(en)
|
2013-02-21 |
2014-08-27 |
Universitätsklinikum Freiburg |
Recombinant bispecific antibody that binds to the CD133 antigen on tumor cells and to the human CD3 T cell receptor
|
|
US20160017058A1
(en)
|
2013-03-14 |
2016-01-21 |
The California Institute For Biomedical Research |
Bispecific antibodies and uses thereof
|
|
RU2015137685A
(ru)
|
2013-03-15 |
2017-04-20 |
ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед |
Композиции антитела в низкой концентрации
|
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
MX2015014608A
(es)
|
2013-04-19 |
2016-03-03 |
Covagen Ag |
Novedosas moleculas de union biespecifica con actividad antitumoral.
|
|
SG11201508528TA
(en)
|
2013-05-02 |
2015-11-27 |
Anaptysbio Inc |
Antibodies directed against programmed death-1 (pd-1)
|
|
EA035322B1
(ru)
|
2013-05-28 |
2020-05-28 |
ДиЭсБи-ЮЭсЭй ЛЛК |
Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения
|
|
SG11201509361TA
(en)
|
2013-05-28 |
2015-12-30 |
Numab Ag |
Novel antibodies
|
|
CN111423511B
(zh)
|
2013-05-31 |
2024-02-23 |
索伦托药业有限公司 |
与pd-1结合的抗原结合蛋白
|
|
TWI725931B
(zh)
|
2013-06-24 |
2021-05-01 |
美商建南德克公司 |
抗ｆｃｒｈ５抗體
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
MX2016000272A
(es)
|
2013-07-12 |
2016-08-03 |
Zymeworks Inc |
Construcciones de unión a los antígenos cd19 y cd3 biespecificos.
|
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
|
PT3702373T
(pt)
|
2013-09-13 |
2022-09-27 |
Beigene Switzerland Gmbh |
Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
|
|
MY176522A
(en)
|
2013-11-04 |
2020-08-13 |
Ichnos Sciences SA |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
|
ES3030987T3
(en)
|
2013-11-27 |
2025-07-03 |
Zymeworks Bc Inc |
Bispecific antigen-binding constructs targeting her2
|
|
CR20160319A
(es)
|
2013-12-12 |
2016-11-08 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
|
|
FI3083686T4
(fi)
|
2013-12-17 |
2023-05-09 |
|
Menetelmiä syöpien hoitamiseksi käyttäen pd-1-akselia sitovia antagonisteja ja taksaaneja
|
|
PE20210107A1
(es)
|
2013-12-17 |
2021-01-19 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
EP3102605B1
(en)
|
2014-02-04 |
2018-11-14 |
Pfizer Inc |
Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
|
|
US10899840B2
(en)
|
2014-02-04 |
2021-01-26 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
SG10201913324PA
(en)
|
2014-05-29 |
2020-03-30 |
Macrogenics Inc |
Tri-specific binding molecules and methods of use thereof
|
|
JP6526189B2
(ja)
|
2014-07-03 |
2019-06-05 |
ベイジーン リミテッド |
抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
|
|
US9611325B2
(en)
|
2014-07-21 |
2017-04-04 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody HER2xCD3
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
CN107124884B
(zh)
|
2014-07-25 |
2022-11-01 |
纪念斯隆-凯特林癌症中心 |
双特异性her2和cd3结合分子
|
|
DK3177643T3
(da)
|
2014-08-04 |
2019-07-15 |
Hoffmann La Roche |
Bispecifikke T-celle-aktiverende antigenbindende molekyler
|
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
|
EP3185866A1
(en)
|
2014-08-25 |
2017-07-05 |
Pfizer Inc. |
Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
|
|
WO2016036678A1
(en)
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
|
EP3689910A3
(en)
|
2014-09-23 |
2020-12-02 |
F. Hoffmann-La Roche AG |
Method of using anti-cd79b immunoconjugates
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
CA2964367C
(en)
|
2014-10-14 |
2024-01-30 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
PT3221359T
(pt)
|
2014-11-17 |
2020-06-23 |
Regeneron Pharma |
Métodos para o tratamento de tumores usando anticorpos biespecíficos cd3xcd20
|
|
US20170326234A1
(en)
|
2014-12-02 |
2017-11-16 |
Celgene Corporation |
Combination therapies
|
|
SG11201704449VA
(en)
|
2014-12-05 |
2017-06-29 |
Genentech Inc |
ANTI-CD79b ANTIBODIES AND METHODS OF USE
|
|
WO2016106160A1
(en)
|
2014-12-22 |
2016-06-30 |
Enumeral Biomedical Holdings, Inc. |
Methods for screening therapeutic compounds
|
|
CN107660214B
(zh)
|
2015-01-08 |
2022-02-08 |
根马布股份公司 |
针对cd3和cd20的双特异性抗体
|
|
CA3225013A1
(en)
|
2015-02-24 |
2016-09-01 |
Bioatla, Llc |
Conditionally active proteins
|
|
CN107709363A
(zh)
|
2015-05-01 |
2018-02-16 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
|
CN107646038B
(zh)
|
2015-05-28 |
2021-08-20 |
基因泰克公司 |
用于检测抗cd3同二聚体的基于细胞的测定
|
|
EP3307282A4
(en)
|
2015-06-12 |
2019-05-01 |
Immunomedics, Inc. |
DISEASE THERAPY WITH CONSTRUCTS OF CHIMERIC ANTIGEN RECEPTOR (CAR) AND T-CELL (CAR-T) OR NK-CELL (CAR-NK) EXPRESSIVE CAR CONSTRUCTS
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
CN107849132B
(zh)
|
2015-06-16 |
2022-03-08 |
豪夫迈·罗氏有限公司 |
人源化的和亲和力成熟的针对FcRH5的抗体和使用方法
|
|
EP3310378B1
(en)
|
2015-06-16 |
2024-01-24 |
F. Hoffmann-La Roche AG |
Anti-cll-1 antibodies and methods of use
|
|
JP2018524312A
(ja)
|
2015-06-17 |
2018-08-30 |
ジェネンテック， インコーポレイテッド |
抗ｈｅｒ２抗体及び使用方法
|
|
DK3313874T3
(da)
|
2015-06-26 |
2021-05-03 |
Univ Southern California |
Maskering af kimære antigen-receptor t-celler til tumorspecifik aktivering
|
|
KR102850929B1
(ko)
|
2015-12-09 |
2025-08-27 |
에프. 호프만-라 로슈 아게 |
항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
|
|
WO2017132279A1
(en)
|
2016-01-25 |
2017-08-03 |
Genentech, Inc. |
Methods for assaying t-cell dependent bispecific antibodies
|
|
CN109923128A
(zh)
|
2016-11-15 |
2019-06-21 |
基因泰克公司 |
用于用抗cd20/抗cd3双特异性抗体进行治疗的给药
|
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
|
US10561686B2
(en)
|
2018-01-12 |
2020-02-18 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
WO2019143636A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
|
IL280875B2
(en)
|
2018-08-31 |
2024-12-01 |
Regeneron Pharma |
Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
|
|
EP3968993A1
(en)
|
2019-05-14 |
2022-03-23 |
F. Hoffmann-La Roche AG |
Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma
|
|
US20220153842A1
(en)
|
2020-11-04 |
2022-05-19 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|